Medication info
Shusta Tablet 2.5mg (Rosuvastatin Calcium)

Shusta Tablet 2.5mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Anguk Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501436 · Approved 2025.06.12 · Insurance code 650206190

Summary

Main use
Improvement of primary hypercholesterolemia and mixed dyslipidemia
Who uses it
Adults
Adult dosage
Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 2.5 or 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, up to a maximum of 20 milligrams once daily. Elderly: No dose adjustment is necessary. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 2.5 or 5 milligrams. Administration of the 40 milligrams dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 2.5 or 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients.

Ingredients

Manufacturer
Anguk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of primary hypercholesterolemia and mixed dyslipidemia

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
View approved original text

This medicine is used for patients with primary hypercholesterolemia, heterozygous familial hypercholesterolemia (type IIa), and mixed dyslipidemia (type IIb). It assists when cholesterol control is difficult solely through diet and exercise, serving as an adjunct to dietary therapy. This helps effectively manage blood cholesterol levels, reducing the risk of cardiovascular diseases. If taken continuously as appropriate for the patient's health condition, good effects can be expected. Therefore, this drug is actively used in the treatment of hypercholesterolemia.

Dosage and Administration

Adult dosage

Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 2.5 or 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, up to a maximum of 20 milligrams once daily. Elderly: No dose adjustment is necessary. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 2.5 or 5 milligrams. Administration of the 40 milligrams dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 2.5 or 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients.

Precautions

This drug should not be administered to certain patients. First, patients with an allergy to any ingredient of this drug or active liver disease should not take it. Additionally, patients with muscle disorders or those taking certain immunosuppressants, and those with severe renal impairment should not use this medication. Pregnant or nursing women, as well as women of childbearing age not using appropriate contraception, should avoid this drug, and it is only to be administered to women of childbearing age if they are highly unlikely to be pregnant and fully aware of the associated risks to the fetus. Patients at high risk for muscle-related side effects, such as those with moderate renal impairment, hypothyroidism, a history of genetic muscle disorders, alcohol dependence, or certain races (e.g., Asian patients) should avoid high doses of this drug. This drug contains lactose and should not be administered to patients with lactose intolerance or related genetic disorders. Caution should be taken for liver function abnormalities or muscle-related side effects when using this drug. In particular, those who consume large amounts of alcohol or have a history of liver disease should regularly have liver enzyme tests. If symptoms such as muscle pain, weakness, or cramps arise, inform a doctor immediately, and if necessary, check for muscle damage through blood tests. If muscle damage indicators are significantly elevated or symptoms become severe, this drug should be discontinued, and it may be resumed at a lower dose once symptoms improve. Furthermore, in the event of acute severe illness or worsening of certain bodily conditions, administration of this drug should be stopped, and if severe myasthenia gravis or ocular myasthenia occurs, usage should be ceased immediately. This drug may interact with other medications, so caution is needed, especially when combined with medications that pose a risk of muscle toxicity. When used with certain drugs, blood concentration of this drug may increase, raising the risk of side effects. Therefore, always consult a doctor or pharmacist about concomitant medications. The safety of this drug in pregnant or nursing women has not been established, thus it should not be used, and women capable of becoming pregnant should use appropriate contraception. In case of overdose, there are no specific antidotes, so treatment should be symptomatic, and liver function as well as muscle damage indicators should be monitored. This drug appears not to significantly affect driving or machine operation capability, but caution is advised as dizziness may occur.

Side effects

Dyspepsia, pruritus, immune thrombocytopenic purpura, facial swelling, shingles, vulvar pruritus, hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, hives, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, headache, dizziness, elevated ALT, chest pain, cough, myalgia, increased CK, constipation, elevated AST, weakness, joint pain, fatigue, numbness, paresthesia, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

Store this drug in a tightly sealed container to prevent exposure to air and moisture, and it is safe to keep it at room temperature between 1 degree and 30 degrees Celsius. This storage method helps maintain the drug's effectiveness and prevents degradation.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.